- Home
- NHI vs NAMS Comparison
NHI vs NAMS Comparison
Compare NHI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NHI | NAMS |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | NHI | NAMS |
|---|---|---|
| Price | $82.76 | $32.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $85.20 | $46.56 |
| AVG Volume (30 Days) | 207.6K | ★ 639.5K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 8.88 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $357,572,000.00 | $35,243,000.00 |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $14.87 | $10.46 |
| P/E Ratio | $25.60 | ★ N/A |
| Revenue Growth | ★ 8.40 | 4.91 |
| 52 Week Low | $65.23 | $14.06 |
| 52 Week High | $82.39 | $42.00 |
Technical Indicators
Market Signals| Indicator | NHI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.22 | 45.94 |
| Support Level | $78.73 | $30.50 |
| Resistance Level | $82.39 | $32.45 |
| Average True Range (ATR) | 1.96 | 1.42 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 96.16 | 47.70 |
Price Performance
Historical ComparisonAbout NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.